Company news

Merck and Addex Pharmaceuticals entered a deal to develop a drug candidate for schizophrenia, under which Merck will pay Addex up to $702 million in cash plus royalties. Geneva-based Addex will receive $22 million as an upfront payment and is eligible for up to $455 million in research, development, regulatory and sales milestones for the first product developed for two uses as well as up to $225 million in additional milestones for a second product developed for two uses.
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.